{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T03:29:38Z","timestamp":1780543778181,"version":"3.54.1"},"reference-count":107,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1097\/01.crd.0000233904.77128.49","type":"journal-article","created":{"date-parts":[[2007,2,7]],"date-time":"2007-02-07T10:33:44Z","timestamp":1170844424000},"page":"76-86","source":"Crossref","is-referenced-by-count":57,"title":["Type 5 Phosphodiesterase Inhibitors in the Treatment of Erectile Dysfunction and Cardiovascular Disease"],"prefix":"10.1097","volume":"15","author":[{"given":"Gautham","family":"Ravipati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"McClung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilbert S.","family":"Aronow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210203","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0090-4295(02)02439-1","article-title":"Phosphodiesterases as therapeutic agents.","volume":"61","author":"Lin","year":"2003","journal-title":"J Urol"},{"key":"R2-4-20210203","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nrd1362","article-title":"Tadalafil and vardenafil: drug discovery.","volume":"3","author":"Neumeyer","year":"2004","journal-title":"Nature Rev Drug Disc"},{"issue":"suppl H","key":"R3-4-20210203","doi-asserted-by":"crossref","first-page":"H19","DOI":"10.1016\/S1520-765X(02)90048-9","article-title":"Phosphodiesterase type 5 inhibition in cardiovascular disease: experimental models and potential clinical applications.","volume":"4","author":"Jackson","year":"2002","journal-title":"Eur Heart J"},{"key":"R4-4-20210203","doi-asserted-by":"crossref","first-page":"13729","DOI":"10.1074\/jbc.274.20.13729","article-title":"Cyclic GMP phospodiesterase-5: target of sildenafil.","volume":"274","author":"Corbin","year":"1999","journal-title":"J Biol Chem"},{"key":"R5-4-20210203","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1056\/NEJM198904203201601","article-title":"Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence.","volume":"320","author":"Saenz de Tejada","year":"1989","journal-title":"N Engl J Med"},{"key":"R6-4-20210203","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0022-5347(01)63097-0","article-title":"Effect of the selective phosphodiesterase type 5 inhibitor sildenafil on erectile dysfunction in the anesthetized dog.","volume":"160","author":"Carter","year":"1998","journal-title":"J Urol"},{"key":"R7-4-20210203","first-page":"1221","article-title":"Cardiovascular Pharmacotherapy.","author":"Melman","year":"1997"},{"key":"R8-4-20210203","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1161\/01.CIR.0000081166.87607.E2","article-title":"Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease.","volume":"108","author":"Reffelmann","year":"2003","journal-title":"Circulation"},{"key":"R9-4-20210203","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrd893","article-title":"Phosphodiesterase 5 inhibitors: current status and potential applications.","volume":"1","author":"Rotella","year":"2002","journal-title":"Nat Rev Drug Disc"},{"key":"R10-4-20210203","doi-asserted-by":"crossref","first-page":"3C","DOI":"10.1016\/S0002-9149(99)00042-9","article-title":"Tissue distribution of phosphodiesterase families and the effect of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro.","volume":"83","author":"Wallis","year":"1999","journal-title":"Am J Cardiol"},{"key":"R11-4-20210203","first-page":"435","article-title":"Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil: review of the literature.","volume":"7","author":"Gresser","year":"2002","journal-title":"Eur J Med Res"},{"key":"R12-4-20210203","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0167-5273(02)00421-7","article-title":"Coronary and systemic hemodynamic effects of sildenafil citrate: from basic science to clinical studies in patients with cardiovascular disease.","volume":"86","author":"Gillies","year":"2002","journal-title":"Int J Cardiol"},{"key":"R13-4-20210203","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1177\/0091270005276847","article-title":"The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction.","volume":"45","author":"Gupta","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"R14-4-20210203","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2165\/00002512-200421020-00005","article-title":"Spotlight on vardenafil in erectile dysfunction.","volume":"21","author":"Keating","year":"2004","journal-title":"Drugs Aging"},{"key":"R15-4-20210203","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/S0735-1097(02)02563-9","article-title":"The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease.","volume":"40","author":"Thadani","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"R16-4-20210203","doi-asserted-by":"crossref","first-page":"336A","DOI":"10.1016\/S0735-1097(03)82023-5","article-title":"The effect of vardenafil, a selective PDE-5 inhibitor, on ischemic threshold, exercise tolerance, and circulatory responses during treadmill exercise tolerance, and circulatory responses during treadmill exercise in men with stable angina pectoris [abstract].","volume":"41","author":"Thadani","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"R17-4-20210203","doi-asserted-by":"crossref","first-page":"19M","DOI":"10.1016\/S0002-9149(03)00828-2","article-title":"Efficacy and tolerability of tadalafil, a novel phosphodiesterase 5 inhibitor, in treatment of erectile dysfunction.","volume":"92","author":"Padma-Nathan","year":"2003","journal-title":"Am J Cardiol"},{"key":"R18-4-20210203","doi-asserted-by":"crossref","first-page":"37M","DOI":"10.1016\/S0002-9149(03)00074-2","article-title":"Cardiovascular effects of tadalafil.","volume":"92","author":"Kloner","year":"2003","journal-title":"Am J Cardiol"},{"key":"R19-4-20210203","doi-asserted-by":"crossref","first-page":"47M","DOI":"10.1016\/S0002-9149(03)00075-4","article-title":"Cardiovascular effects of tadalafil in patients on common antihypertensive therapies.","volume":"92","author":"Kloner","year":"2003","journal-title":"Am J Cardiol"},{"key":"R20-4-20210203","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0094-0143(21)00690-X","article-title":"The epidemiology of erectile dysfunction.","volume":"22","author":"Bent","year":"1995","journal-title":"Urol Clin North Am"},{"key":"R21-4-20210203","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0022-5347(17)34871-1","article-title":"Impotence and its medical and psychological correlates: results of the Massachusetts Male Aging Study.","volume":"151","author":"Feldman","year":"1994","journal-title":"J Urol"},{"key":"R22-4-20210203","doi-asserted-by":"crossref","first-page":"1M","DOI":"10.1016\/S0002-9149(03)00073-0","article-title":"Erectile dysfunction and cardiovascular risk factors.","volume":"92","author":"Kloner","year":"2003","journal-title":"Am J Cardiol"},{"issue":"suppl 5","key":"R23-4-20210203","doi-asserted-by":"crossref","first-page":"29C","DOI":"10.1016\/S0002-9149(99)00045-4","article-title":"Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease.","volume":"83","author":"Conti","year":"1999","journal-title":"Am J Cardiol"},{"key":"R24-4-20210203","doi-asserted-by":"crossref","first-page":"26M","DOI":"10.1016\/S0002-9149(02)03368-4","article-title":"Sildenafil in patients with cardiovascular disease.","volume":"92","author":"Brindis","year":"2003","journal-title":"Am J Cardiol"},{"key":"R24A-4-20210203","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1161\/01.CIR.0000133278.81226.C9","article-title":"Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncomplicated type 2 diabetic patients.","volume":"110","author":"Gazzaruso","year":"2004","journal-title":"Circulation"},{"key":"R25-4-20210203","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/S0022-5347(01)66200-1","article-title":"Study of etiologic relationship of arterial atherosclerosis to corporal veno-occlusive dysfunction in the rabbit.","volume":"155","author":"Azadzoi","year":"1996","journal-title":"J Urol"},{"key":"R26-4-20210203","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2337\/diacare.26.2.279","article-title":"Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes.","volume":"26","author":"Stuckey","year":"2003","journal-title":"Diabetes Care"},{"key":"R27-4-20210203","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0025-6196(11)62632-3","article-title":"Erectile dysfunction and cardiovascular disease.","volume":"79","author":"Russell","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"R28-4-20210203","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.jacc.2005.06.068","article-title":"Subclinical coronary artery atherosclerosis in patients with erectile dysfunction.","volume":"46","author":"Chiurlia","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R28A-4-20210203","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1001\/jama.294.23.2996","article-title":"Erectile dysfunction and subsequent cardiovascular disease.","volume":"294","author":"Thompson","year":"2005","journal-title":"JAMA"},{"key":"R29-4-20210203","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1006\/pmed.2000.0643","article-title":"Erectile dysfunction and cardiac risk factors: prospective results from the Massachusetts Male Aging Study.","volume":"30","author":"Feldman","year":"2000","journal-title":"Prev Med"},{"key":"R30-4-20210203","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(98)00015-4","article-title":"Acute myocardial infarction associated with sildenafil.","volume":"352","author":"Feenstra","year":"1998","journal-title":"Lancet"},{"key":"R31-4-20210203","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1742-1241.2003.tb10566.x","article-title":"Clinical trials of sildenafil citrate (Viagra) demonstrate no increase in risk of myocardial infarction and cardiovascular death compared with placebo.","volume":"57","author":"Mittleman","year":"2003","journal-title":"Int J Clin Pract"},{"key":"R32-4-20210203","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.amjcard.2005.03.097","article-title":"Evaluation of acute risk of myocardial infarction in men treated with sildenafil citrate.","volume":"96","author":"Mittleman","year":"2005","journal-title":"Am J Cardiol"},{"key":"R33-4-20210203","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1161\/01.CIR.0000146906.42375.D3","article-title":"Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction.","volume":"110","author":"Kloner","year":"2004","journal-title":"Circulation"},{"key":"R34-4-20210203","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1056\/NEJM200006013422201","article-title":"Hemodynamic effects of sildenafil in men with severe coronary artery disease.","volume":"342","author":"Hermann","year":"2000","journal-title":"N Engl J Med"},{"key":"R35-4-20210203","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0735-1097(98)00656-1","article-title":"ACC\/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology\/American Heart Association.","volume":"33","author":"Cheitlin","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"R36-4-20210203","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.amjhyper.2004.07.004","article-title":"Sildenafil citrate for erectile dysfunction in men receiving multiple antihypertensive agents: a randomized controlled trial.","volume":"17","author":"Pickering","year":"2005","journal-title":"Am J Hypertens"},{"key":"R37-4-20210203","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0002-9149(00)00896-1","article-title":"Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton Consensus Panel.","volume":"86","author":"De Busk","year":"2000","journal-title":"Am J Cardiol"},{"key":"R38-4-20210203","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.2165\/00003495-200464140-00003","article-title":"Treatment of erectile dysfunction in patients with cardiovascular disease. Guide to drug selection.","volume":"64","author":"Jackson","year":"2004","journal-title":"Drugs"},{"key":"R39-4-20210203","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1161\/01.CIR.102.25.3068","article-title":"Sympathetic activation by sildenafil.","volume":"102","author":"Phillips","year":"2000","journal-title":"Circulation"},{"key":"R40-4-20210203","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1161\/01.CIR.102.3.275","article-title":"Sildenafil (Viagra) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current.","volume":"102","author":"Geelen","year":"2000","journal-title":"Circulation"},{"key":"R41-4-20210203","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S0735-1097(00)01049-4","article-title":"Sildenafil citrate (Viagra) does not exacerbate myocardial ischemia in canine models of coronary artery stenosis.","volume":"37","author":"Przyklenk","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"R42-4-20210203","doi-asserted-by":"crossref","first-page":"H2319","DOI":"10.1152\/ajpheart.2000.279.5.H2319","article-title":"Effect of sildenafil on coronary active and reactive hyperemia.","volume":"279","author":"Chen","year":"2000","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"R43-4-20210203","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1161\/01.CIR.102.24.2997","article-title":"Cyclic nucleotide phosphodiesterase type 5 activity limits blood flow to hypoperfused myocardium during exercise.","volume":"102","author":"Traverse","year":"2000","journal-title":"Circulation"},{"key":"R44-4-20210203","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.jacc.2005.11.060","article-title":"Sildenafil improves coronary artery patency in a canine model of platelet-mediated cyclic coronary occlusion after thrombolysis.","volume":"47","author":"Lewis","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"R45-4-20210203","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/S0735-1097(02)02139-3","article-title":"The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia.","volume":"40","author":"Halcox","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"R46-4-20210203","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1161\/01.CIR.102.20.2516","article-title":"Effects of sildenafil citrate (Viagra) combined with nitrate on the heart.","volume":"102","author":"Ishikura","year":"2000","journal-title":"Circulation"},{"key":"R47-4-20210203","first-page":"H1263","article-title":"Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits.","volume":"283","author":"Ockaili","year":"2002","journal-title":"Am J Physiol"},{"key":"R48-4-20210203","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1161\/CIRCULATIONAHA.105.540500","article-title":"Sildenafil inhibits \u03b2-adrenergic-stimulated cardiac contractility in humans.","volume":"112","author":"Borlaug","year":"2005","journal-title":"Circulation"},{"key":"R49-4-20210203","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1161\/CIRCULATIONAHA.105.577627","article-title":"Type 5 phosphodiesterase inhibition. The focus shifts to the heart [editorial].","volume":"112","author":"Semigran","year":"2005","journal-title":"Circulation"},{"key":"R50-4-20210203","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1096\/fj.00-0538com","article-title":"Cardiac phosphodiesterase 5 (cGMP-specific) modulates \u03b2-adrenergic signaling in vivo and is down-regulated in heart failure.","volume":"15","author":"Senzaki","year":"2001","journal-title":"FASEB J"},{"key":"R51-4-20210203","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1161\/01.CIR.74.5.1124","article-title":"Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium.","volume":"74","author":"Murry","year":"1986","journal-title":"Circulation"},{"key":"R52-4-20210203","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.yjmcc.2003.11.001","article-title":"Cardioprotection with phosphodiesterase-5 inhibition-a novel preconditioning strategy.","volume":"36","author":"Kukreja","year":"2004","journal-title":"J Mol Cell Cardiol"},{"key":"R53-4-20210203","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.vph.2005.02.010","article-title":"Pharmacological preconditioning with sildenafil: basic mechanisms and clinical implications.","volume":"42","author":"Kukreja","year":"2005","journal-title":"Vasc Pharmacol"},{"key":"R54-4-20210203","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1161\/01.RES.0000066853.09821.98","article-title":"Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart.","volume":"92","author":"Salloum","year":"2003","journal-title":"Circ Res"},{"key":"R55-4-20210203","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1161\/01.CIR.0000156407.59837.C1","article-title":"Sildenafil and endothelial dysfunction in humans.","volume":"111","author":"Gross","year":"2005","journal-title":"Circulation"},{"key":"R56-4-20210203","doi-asserted-by":"crossref","first-page":"H2425","DOI":"10.1152\/ajpheart.1999.277.6.H2425","article-title":"Opening of mitochondrial KATP channel induces early and delayed cardioprotective effects: role of nitric oxide.","volume":"277","author":"Ockaili","year":"1999","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"R57-4-20210203","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1161\/01.CIR.0000155252.23933.2D","article-title":"Sildenafil prevents endothelial dysfunction induced by ischemia and reperfusion via opening of adenosine triphosphate-sensitive potassium channels.","volume":"111","author":"Gori","year":"2005","journal-title":"Circulation"},{"key":"R58-4-20210203","doi-asserted-by":"crossref","first-page":"12944","DOI":"10.1074\/jbc.M404706200","article-title":"Phosphodiesterase-5 inhibitor, sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis: essential role of NO signaling.","volume":"280","author":"Das","year":"2005","journal-title":"J Biol Chem"},{"key":"R59-4-20210203","doi-asserted-by":"crossref","first-page":"M113","DOI":"10.1093\/gerona\/56.2.M113","article-title":"Sildenafil citrate (Viagra) improves erectile function in elderly patients with erectile dysfunction: a subgroup analysis.","volume":"56A","author":"Wagner","year":"2001","journal-title":"J Gerontol"},{"key":"R60-4-20210203","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0895-7061(00)01177-8","article-title":"Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy.","volume":"14","author":"Kloner","year":"2001","journal-title":"Am J Hypertens"},{"key":"R61-4-20210203","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/jama.287.6.719","article-title":"Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized crossover trial.","volume":"287","author":"Arruda-Olson","year":"2002","journal-title":"JAMA"},{"key":"R62-4-20210203","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1161\/CIRCULATIONAHA.104.523324","article-title":"Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.","volume":"112","author":"Fries","year":"2005","journal-title":"Circulation"},{"key":"R63-4-20210203","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.105.577643","article-title":"More potential for sildenafil than potency [editorial].","volume":"112","author":"Mahler","year":"2005","journal-title":"Circulation"},{"key":"R64-4-20210203","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.athoracsur.2004.02.125","article-title":"Sildenafil: emerging cardiovascular indications.","volume":"78","author":"Raja","year":"2004","journal-title":"Ann Thorac Surg"},{"key":"R65-4-20210203","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1161\/01.CIR.0000074226.20466.B1","article-title":"Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension.","volume":"107","author":"Sebhki","year":"2003","journal-title":"Circulation"},{"key":"R66-4-20210203","doi-asserted-by":"crossref","first-page":"169","DOI":"10.7326\/0003-4819-141-3-200408030-00005","article-title":"Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp.","volume":"141","author":"Ghofrani","year":"2004","journal-title":"Ann Intern Med"},{"key":"R67-4-20210203","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1161\/hc2901.093117","article-title":"Sildenafil inhibits hypoxia-induced pulmonary hypertension.","volume":"104","author":"Zhao","year":"2001","journal-title":"Circulation"},{"key":"R68-4-20210203","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1161\/01.CIR.0000016641.12984.DC","article-title":"Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide.","volume":"105","author":"Michelakis","year":"2002","journal-title":"Circulation"},{"key":"R69-4-20210203","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1161\/01.CIR.0000050653.10758.6B","article-title":"Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic peptide activity.","volume":"107","author":"Zhao","year":"2003","journal-title":"Circulation"},{"key":"R70-4-20210203","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1161\/01.CIR.0000099502.17776.C2","article-title":"Long-term treatment with oral sildenafil is safe, and improves functional capacity, and hemodynamics in patients with pulmonary arterial hypertension.","volume":"108","author":"Michelakis","year":"2003","journal-title":"Circulation"},{"key":"R71-4-20210203","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.4065\/78.10.1207","article-title":"Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy.","volume":"78","author":"Bhatia","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"R72-4-20210203","first-page":"404","article-title":"Chronic oral sildenafil therapy in severe pulmonary artery hypertension.","volume":"54","author":"Kothari","year":"2002","journal-title":"Indian Heart J"},{"key":"R73-4-20210203","first-page":"55","article-title":"The efficacy and tolerability of sildenafil in patients with moderate-to-severe pulmonary hypertension.","volume":"55","author":"Bharani","year":"2003","journal-title":"Indian Heart J"},{"key":"R74-4-20210203","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1378\/chest.123.4.989","article-title":"Sildenafil for pulmonary arterial hypertension. Exciting, but protection required.","volume":"123","author":"Mehta","year":"2003","journal-title":"Chest"},{"key":"R74A-4-20210203","doi-asserted-by":"crossref","first-page":"851e1","DOI":"10.1016\/j.ahj.2005.09.006","article-title":"A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension.","volume":"151","author":"Singh","year":"2006","journal-title":"Am Heart J"},{"key":"R75-4-20210203","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1183\/09031936.04.00051104","article-title":"Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension.","volume":"24","author":"Hoeper","year":"2004","journal-title":"Eur Respir J"},{"key":"R76-4-20210203","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1365-2125.2005.02383.x","article-title":"Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension.","volume":"60","author":"Paul","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"R77-4-20210203","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0735-1097(03)00555-2","article-title":"Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension.","volume":"42","author":"Ghofrani","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"R78-4-20210203","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension.","volume":"353","author":"Galie","year":"2005","journal-title":"N Engl J Med"},{"key":"R79-4-20210203","first-page":"93A","article-title":"Hemodynamic effects of sildenafil citrate in patients with pulmonary arterial hypertension (PAH).","volume":"18","author":"Rubin","year":"2005","journal-title":"Am J Hypertens"},{"key":"R80-4-20210203","first-page":"65","article-title":"Sildenafil (Revatio) for pulmonary arterial hypertension.","volume":"47","year":"2005","journal-title":"Med Lett Drugs Ther"},{"key":"R81-4-20210203","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1161\/01.CIR.87.2.440","article-title":"Impairment of endothelium-dependent pulmonary artery relaxation in children with congenital heart disease and abnormal pulmonary hemodynamics.","volume":"87","author":"Celermajer","year":"1993","journal-title":"Circulation"},{"issue":"suppl 1","key":"R82-4-20210203","first-page":"II167","article-title":"Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease.","volume":"108","author":"Schulze-Neick","year":"2003","journal-title":"Circulation"},{"key":"R83-4-20210203","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(02)11024-5","article-title":"Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomized controlled trial.","volume":"360","author":"Ghofrani","year":"2002","journal-title":"Lancet"},{"key":"R83A-4-20210203","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1378\/chest.129.2.417","article-title":"Pulmonary hemodynamic responses to brain natriuretic peptide and sildenafil in patients with pulmonary arterial hypertension.","volume":"129","author":"Klinger","year":"2006","journal-title":"Chest"},{"key":"R84-4-20210203","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.1161\/CIRCULATIONAHA.104.473371","article-title":"Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension. Twelve-month clinical trial of a single-drug, open-label, pilot study.","volume":"111","author":"Humpl","year":"2005","journal-title":"Circulation"},{"key":"R85-4-20210203","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1378\/chest.123.4.1293","article-title":"Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension.","volume":"123","author":"Stiebellehner","year":"2003","journal-title":"Chest"},{"key":"R85A-4-20210203","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1001\/archinte.166.16.1763","article-title":"A double-blind, placebo-controlled, crossover study of sildenafil in obstructive sleep apnea.","volume":"166","author":"Roizenblatt","year":"2006","journal-title":"Arch Intern Med"},{"key":"R86-4-20210203","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1161\/01.CIR.0000027149.83473.B6","article-title":"Sildenafil effects on exercise, neurohormonal activation, and erective dysfunction in congestive heart failure: a double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction.","volume":"106","author":"Bocchi","year":"2002","journal-title":"Circulation"},{"key":"R87-4-20210203","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.amjcard.2005.06.091","article-title":"Effect of sildenafil on cardiac performance in patients with heart failure.","volume":"96","author":"Hirata","year":"2005","journal-title":"Am J Cardiol"},{"key":"R87A-4-20210203","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.jacc.2006.05.052","article-title":"Erectile dysfunction in heart failure patients.","volume":"48","author":"Schwarz","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"R88-4-20210203","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1001\/archinte.164.5.514","article-title":"Use of sildenafil for safe improvement of erectile function and quality of life in men with New York Heart Association classes II and III congestive heart failure.","volume":"164","author":"Webster","year":"2004","journal-title":"Arch Intern Med"},{"key":"R89-4-20210203","doi-asserted-by":"crossref","first-page":"H1935","DOI":"10.1152\/ajpheart.1999.276.6.H1935","article-title":"Vasorelaxing effects of atrial and brain natriuretic peptides on coronary circulation in heart failure.","volume":"276","author":"Matsumoto","year":"1999","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"R90-4-20210203","doi-asserted-by":"crossref","first-page":"H1513","DOI":"10.1152\/ajpheart.00529.2001","article-title":"Effect of PDE5 inhibition on coronary hemodynamics in pacing-induced heart failure.","volume":"284","author":"Chen","year":"2003","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"R91-4-20210203","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0735-1097(00)00790-7","article-title":"Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure.","volume":"36","author":"Katz","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"R92-4-20210203","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1016\/j.jacc.2004.09.041","article-title":"The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure.","volume":"44","author":"Guazzi","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"R93-4-20210203","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJM199507273330403","article-title":"Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension.","volume":"333","author":"Giad","year":"1995","journal-title":"N Engl J Med"},{"key":"R94-4-20210203","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1378\/chest.127.5.1647","article-title":"Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension. Combined administration with inhaled nitric oxide.","volume":"127","author":"Lepore","year":"2005","journal-title":"Chest"},{"key":"R95-4-20210203","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1161\/01.CIR.102.14.1718","article-title":"Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management.","volume":"102","author":"Moraes","year":"2000","journal-title":"Circulation"},{"key":"R96-4-20210203","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.amjcard.2004.07.157","article-title":"Efficacy and safety of sildenafil in the evaluation of pulmonary hypertension in severe heart failure.","volume":"94","author":"Alaeddini","year":"2004","journal-title":"Am J Cardiol"},{"key":"R97-4-20210203","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1161\/01.CIR.103.7.916","article-title":"Gas exchange efficiency in congestive heart failure II.","volume":"103","author":"Johnson","year":"2001","journal-title":"Circulation"},{"key":"R98-4-20210203","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1152\/jappl.1957.11.2.290","article-title":"Relative importance of diffusion and chemical reaction rate of exchange of gases in human lung, with special reference to true diffusing capacity of blood in the lung capillaries.","volume":"11","author":"Roughton","year":"1957","journal-title":"J Appl Physiol"},{"key":"R99-4-20210203","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S0735-1097(03)00914-8","article-title":"Improvement of alveolar\u2013capillary membrane diffusing capacity with exercising training in chronic heart failure.","volume":"42","author":"Guazzi","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"R100-4-20210203","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1067\/mhj.2002.121547","article-title":"Effects of sildenafil (Viagra) on cardiac repolarization and on autonomic control in subjects with chronic heart failure.","volume":"143","author":"Piccirillo","year":"2002","journal-title":"Am Heart J"},{"key":"R101-4-20210203","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1161\/01.CIR.0000160359.49478.C2","article-title":"Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity.","volume":"111","author":"Fisher","year":"2005","journal-title":"Circulation"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00045415-200703000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T20:15:14Z","timestamp":1707596114000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045415-200703000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":107,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/01.crd.0000233904.77128.49","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2007,3]]}}}